Literature DB >> 11298095

Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs.

C Shimizu1, M Kubo, K Takano, A Takano, H Kijima, H Saji, I Katsuyama, H Sasano, T Koike.   

Abstract

A 35-year-old Japanese woman presented with a phaeochromocytoma and demonstrated marked inflammatory reactions and pyrexia as a result of excessive production of interleukin-6 (IL-6) by the tumour. Serum IL-6 level was 262 ng/l (normal; < 4.0 ng/l). Fever and inflammatory markers were largely overcome by the administration of the nonsteroidal anti-inflammatory drug, naproxen, and all symptoms disappeared soon after the tumour was excised. Immunohistochemical study revealed positive staining using an antihuman IL-6 antibody and Northern analysis showed increased IL-6 mRNA levels in the tumour. Cultured tumour cells showed IL-6 protein synthesis, and nonsteroidal anti-inflammatory drugs such as naproxen and indomethacin directly inhibited IL-6 release. These results indicate that the effects of naproxen in vivo were due, at least in part, to direct suppression of IL-6 secretion from the tumour.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298095     DOI: 10.1046/j.1365-2265.2001.01082.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Pheochromocytoma: a permanent challenge for the clinical endocrinologist.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 2.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Ectopic hormone-secreting pheochromocytoma: a francophone observational study.

Authors:  James Kirkby-Bott; Laurent Brunaud; Muriel Mathonet; Etienne Hamoir; Jean-Louis Kraimps; Christophe Trésallet; Laurence Amar; Alexandre Rault; Jean-Francois Henry; Bruno Carnaille
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 4.  Functioning adrenocortical oncocytoma: the first documented case producing interleukin-6 and review of the literature.

Authors:  T Akatsu; K Kameyama; K Araki; T Ashizawa; G Wakabayashi; M Kitajima
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

5.  Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome.

Authors:  M Minetto; A Dovio; M Ventura; S Cappia; F Daffara; M Terzolo; A Angeli
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

6.  Interleukin-6-producing pheochromocytoma presenting with fever of unknown origin.

Authors:  Sema Yarman; Ozlem Soyluk; Esma Altunoglu; Refik Tanakol
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  IL-6-Producing, Noncatecholamines Secreting Pheochromocytoma Presenting as Fever of Unknown Origin.

Authors:  Marco Ciacciarelli; Davide Bellini; Andrea Laghi; Alessandro Polidoro; Antonio Pacelli; Anna Giulia Bottaccioli; Giuseppina Palmaccio; Federica Stefanelli; Piera Clemenzi; Luisa Carini; Luigi Iuliano; Cesare Alessandri
Journal:  Case Rep Med       Date:  2016-08-07

8.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01

9.  Perioperative management of a patient undergoing resection of interleukin-6 producing pheochromocytoma.

Authors:  Masahiro Kuroki; Hiroto Suzuki; Misato Kurota; Masaki Nakane; Kaneyuki Kawamae
Journal:  JA Clin Rep       Date:  2021-06-11

10.  Interleukin-6 producing pheochromocytoma/paraganglioma: case series from a tertiary referral centre for pheochromocytomas and paragangliomas.

Authors:  A C Meijs; M A Schroijen; M Snel; E P M Corssmit
Journal:  J Endocrinol Invest       Date:  2021-03-14       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.